Fucoxanthin Alleviates Lipopolysaccharide-Induced Inflammation and Immunosuppression in RAW264.7 Macrophages

Dokl Biochem Biophys. 2023 Apr;509(1):81-85. doi: 10.1134/S1607672922600166. Epub 2023 Jun 20.

Abstract

Fucoxanthin (FX) has been reported to reduce mortality in mouse models of sepsis, but its exact cause remains to be determined. In the present study, we evaluated the immunomodulatory properties of FX in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. Our results showed that FX could not only suppress the immune activation responses caused by LPS primary stimulation, but also antagonize LPS restimulation-induced immunosuppression in macrophages. The immunomodulatory capabilities of FX was mainly demonstrated by regulating the production of the inflammatory mediator under different LPS stimuli. Furthermore, we found that adenosine monophosphate-activated protein kinase (AMPK) activation was required for FX's anti-inflammatory and anti-immunosuppressive activities. Our results complement existing data supporting the clinical potential for FX in treating sepsis.

Keywords: fucoxanthin; immunosuppression; inflammation; macrophage.

MeSH terms

  • Animals
  • Immunosuppression Therapy
  • Inflammation / chemically induced
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Lipopolysaccharides* / metabolism
  • Lipopolysaccharides* / toxicity
  • Macrophages / metabolism
  • Mice
  • Sepsis*

Substances

  • Lipopolysaccharides
  • fucoxanthin